Bichat free no signup
04-Dec-2017 15:32
Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin group and 7 (3%) in the placebo group (P = .08).The azithromycin group had increased mortality, with a 2-year survival of 56.6% (95% CI, 50.2%-63.7%) vs 70.1% (95% CI, 64.2%-76.5%) in the placebo group (unadjusted HR, 1.5; 95% CI, 1.1-2.0; P = .02).Additional authors on the study were Yuan Chen, Andrea Rawlings, Roger Blumenthal, Josef Coresh and Elizabeth Selvin of The Johns Hopkins University, and Ron Hoogeveen and Christie Ballantyne of Baylor University.The study was funded by the National Diabetes and Digestive and Kidney Diseases grants (R01DK089174 and K24DK106414); National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C); Roche Diagnostics; Abbott Diagnostics; Amarin; Amgen; Eli Lilly; Esperion; Novartis; Pfizer; Otsuka; Regeneron; Sanofi-Synthelabo; and Takeda.From the blood samples, the ARIC scientists performed high-sensitivity cardiac troponin testing, a way of measuring a protein involved in muscle contraction levels, which rise when there is heart damage from a heart attack or blocked artery.A troponin value greater than or equal to 14 nanograms per liter of blood indicates heart damage.
Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay J, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker L, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G, for the ALLOZITHRO Study Investigators.
Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT).